Anti-CD133 (Prominin-1) Antibody, clone 2F8, ZooMAb® Rabbit Monoclonal

Description

• General description: We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.
• Specificity: Clone 2F8 is a ZooMAb rabbit recombinant monoclonal antibody that specifically detects CD133 (Prominin-1). It targets an epitope with in 77 amino acids fromt the N-terminal extracellualr domain.
• Immunogen: His-tagged recombinant fragment corresponding to 77 amino acids from the N-terminal region of human CD133 (Prominin-1).
• Application: Anti-CD133 (Prominin-1), clone 2F8 ZooMAb, Cat. No. ZRB1013, is a recombinant Rabbit Monoclonal Antibody that specifically targets Prominin (CD133) and has been tested for use in Immunofluorescence, Immunohistochemistry (Paraffin), and Western Blotting.
• Target description: Prominin-1 (UniProt: O43490; also known as Antigen AC133, Prominin-like protein 1, CD133) is encoded by the PROM1 (also known as PROML1, MSTP061) gene (Gene ID: 8842) in human. CD133 (Prominin-1) is multi-pass cell-surface glycoprotein that plays a role in cell differentiation, proliferation and apoptosis. It binds cholesterol in cholesterol-containing plasma membrane microdomains and may play a role in the organization of the apical plasma membrane in epithelial cells. During early retinal development CD133 acts as a key regulator of disk morphogenesis. Defects in PROM1 gene are known to cause retinitis pigmentosa, cone-rod dystrophy, and retinal macular dystrophy 2. Higher levels of CD133 have been reported in several cancer cell types, including various leukemias, retinoblastomas, glioblastomas, and kidney carcinomas. Higher levels of CD133 are also observed in pancreatic, gastric, colorectal, and hepatocellular cancers. It is also considered as a marker of stem cells in the adult small intestine that are susceptible to transformation into tumors retaining a fraction of mutant Prom1+ tumor cells. This ZooMAb recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Zhu, L., et al. (2009). Nature 477 (7229); 603-607).
• Physical form: Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.
• Reconstitution: 300 μg/mL after reconstitution at 25 μL. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
• Storage and Stability: Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.
• Legal Information: ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany
• Disclaimer: Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.